Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. EntreMed is a clinical-stage pharmaceutical company focused on developing the next generation of multi-mechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed's goal is to develop and commercialise new compounds based on its expertise in the science of angiogenesis, cell cycle regulation and inflammation. Unlike other angiogenesis compounds, EntreMed's product candidates target disease-associated endothelial cells only and do not disrupt normal biological processes. As a result, its drug candidates have shown a strong safety profile with neither toxicity nor clinically significant side effects reported to date. The company has a rich pipeline, consisting primarily of small molecules and peptides, under development and in preclinical studies.

EntreMed believes its compounds differ from those being developed by other companies as they target or turn-off the angiogenesis cascade at the most effective point - endothelial cell proliferation and migration that is only associated with angiogenesis involved in the diseases. According to EntreMed, compounds that target mechanisms prior to this signature event, for instance interfering with single growth factors or their receptors, may not be specific enough to be effective and have shown early signs of toxicity, side effects or drug resistance. Compounds targeting the steps that follow endothelial cell proliferation and migration, such as adhesion molecules or smooth muscles, occur too late in the process and may not be effective. EntreMed believes endothelial cell proliferation and migration is the key step in the process of angiogenesis and will prove to be the most effective and safest approach to target, with the least negative effect on the body's natural processes, and with reduced likelihood of drug resistance.